Literature DB >> 18036519

Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1.

Elena Fumagalli1, Marcella Funicello, Thomas Rauen, Marco Gobbi, Tiziana Mennini.   

Abstract

Riluzole exerts a neuroprotective effect through different mechanisms, including action on glutamatergic transmission. We investigated whether this drug affects glutamate transporter-mediated uptake, using clonal cell lines stably expressing the rat glutamate transporters GLAST, GLT1 or EAAC1. We found that riluzole significantly increased glutamate uptake in a dose-dependent manner; kinetic analysis indicated that the apparent affinity of glutamate for the transporters was significantly increased, with similar effects in the three cell lines. This may facilitate the buffering of excessive extracellular glutamate under pathological conditions suggesting that riluzole's neuroprotective action might be partly mediated by its activating effect on glutamate uptake.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036519     DOI: 10.1016/j.ejphar.2007.10.023

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  79 in total

Review 1.  Glutamate transporters in brain ischemia: to modulate or not?

Authors:  Weronika Krzyżanowska; Bartosz Pomierny; Magłorzata Filip; Joanna Pera
Journal:  Acta Pharmacol Sin       Date:  2014-03-31       Impact factor: 6.150

2.  Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.

Authors:  Alice Y C Liu; Rohan Mathur; Newton Mei; Christopher G Langhammer; Bruce Babiarz; Bonnie L Firestein
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

3.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

4.  Fluoxetine and Riluzole Mitigates Manganese-Induced Disruption of Glutamate Transporters and Excitotoxicity via Ephrin-A3/GLAST-GLT-1/Glu Signaling Pathway in Striatum of Mice.

Authors:  Zhipeng Qi; Xinxin Yang; Yanqi Sang; Yanan Liu; Jiashuo Li; Bin Xu; Wei Liu; Miao He; Zhaofa Xu; Yu Deng; Jinghai Zhu
Journal:  Neurotox Res       Date:  2020-05-29       Impact factor: 3.911

5.  Glutamate transporter type 3 participates in maintaining morphine-induced conditioned place preference.

Authors:  Li Wan; Jiangjiang Bi; Jun Li; Zhiyi Zuo
Journal:  Neuroscience       Date:  2017-01-01       Impact factor: 3.590

6.  Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models.

Authors:  Holly C Hunsberger; Sharay E Setti; Ryan T Heslin; Jorge E Quintero; Greg A Gerhardt; Miranda N Reed
Journal:  J Vis Exp       Date:  2017-05-03       Impact factor: 1.355

7.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

8.  Activation of glutamate transporters in the locus coeruleus paradoxically activates descending inhibition in rats.

Authors:  Ken-ichiro Hayashida; Renee A Parker; James C Eisenach
Journal:  Brain Res       Date:  2010-01-06       Impact factor: 3.252

Review 9.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.

Authors:  M Banasr; G M I Chowdhury; R Terwilliger; S S Newton; R S Duman; K L Behar; G Sanacora
Journal:  Mol Psychiatry       Date:  2008-09-30       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.